ArticleBMC women's health2025
Characteristics and prognosis of Her2-negative breast cancer expressing unbalanced hormone receptor.
Article in BMC women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Hormone receptors(HRs), including the Estrogen receptor(ER) and Progesterone receptor(PR), are essential indicators for Breast cancer therapy, while the unbalanced expression effect remains unclear. 106,742 women diagnosed with HER2-negative BC in SEER from 2010 to 2015 were divided into four groups: ER-negative PR-negative (NN), ER-negative PR-positive (NP), ER-positive PR-negative (PN), ER-positive PR-positive (PP). The survival rate of NP was equal to NN (P = 0.65, Hazard Ratio(HR) = 0.960, 95%Confidence Index(CI):0.807-1.144), but worse than PP(P = 0.00017, HR = 0.695, 95%CI:0.575-0.874). The curve of PN was lower than PP(P < 0.0001, HR = 0.753, 95%CI:0.706-0.803), but significantly higher than NN(P < 0.0001, HR = 0.808, 95%CI:0.754-0.866). The effect of PN was worse than that of PP (P_Surgery < 0.0001, HR = 0.834, 95%CI:0.774 to 0.899; P_Radiation < 0.0001, HR = 0.808, 95%CI:0.726-0.884; P_Chemotherapy < 0.0001, HR = 0.812, 95%CI:0.748-0.881; P_Systemic.therapy < 0.0001, HR = 0.799, 95%CI:0.735-0.869). The C-index of NP and PN prediction models were 0.697 (95%CI: 0.654-1.128) and 0.750 (95%CI: 0.733-0.760), respectively, showing moderate effects. HER2-negative BC with unbalanced HRs expression differs from those with consistent expression. NP and PN have lower long-term survival rates than PP even after systemic treatment. Endocrine resistance may be the cause of poor survival of NP and PN, and should be combined with other treatments such as actual intensive chemotherapy. Although the clinical number of NP breast cancer is small, it still needs attention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.